Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter McLaughlin

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
The Journal of Infectious Diseases|October 21, 2006
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphomaAmar Safdar, M Alma Rodriguez, Luis E Fayad, et al.
British Journal of Haematology|April 2, 2015
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomasFelipe Samaniego, Fredrick Hagemeister, Jorge E Romaguera, et al.
Cancer|January 28, 2003
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaJorge E Romaguera, L Jeffrey Medeiros, Frederick B Hagemeister, et al.
British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
British Journal of Haematology|October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaYasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Cancer|May 19, 2017
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapyJessica P Hwang, Maria E Suarez-Almazor, Scott B Cantor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer CenterApostolia M Tsimberidou, Sijin Wen, Susan O'Brien, et al.
British Journal of Haematology|March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized StudyLoretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
The Journal of Infectious Diseases|October 21, 2006
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphomaAmar Safdar, M Alma Rodriguez, Luis E Fayad, et al.
British Journal of Haematology|April 2, 2015
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomasFelipe Samaniego, Fredrick Hagemeister, Jorge E Romaguera, et al.
Cancer|January 28, 2003
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaJorge E Romaguera, L Jeffrey Medeiros, Frederick B Hagemeister, et al.
British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
British Journal of Haematology|October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaYasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Cancer|May 19, 2017
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapyJessica P Hwang, Maria E Suarez-Almazor, Scott B Cantor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer CenterApostolia M Tsimberidou, Sijin Wen, Susan O'Brien, et al.
British Journal of Haematology|March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized StudyLoretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
Pageof 12